Business · Companies · 2 hrs ago
Cipla expects US recovery as respiratory launches and biosimilars advance
Indian drugmaker Cipla reported a softer September quarter year on year, partly because US sales faced a high comparison and sales of active pharmaceutical ingredients were weak.
Revenue and profit still grew from the previous quarter, helped by India, where sales of several types of medicines rose.
The company is looking for new respiratory products to revive US growth after a difficult year there.
Cipla expects US revenue to exceed $1 billion in FY27, up from $780 million the previous year, and plans 45 to 50 product filings over three years.
It has also agreed to sell a biosimilar version of cancer drug Keytruda in the US and Canada, a potential long-term growth driver.
Its operating margin fell compared with a year earlier, but Cipla kept its FY27 margin forecast at 18.5% to 20% and expects improvement in the second half.
The company’s recovery now depends on launches and product mix, while its shares have recently underperformed the healthcare index.
Cipla expects its US business to recover, with respiratory product launches and a growing biosimilar pipeline supporting growth.
The company expects US revenue to exceed $1 billion by the end of FY27, compared with $780 million in the previous year.
Its September-quarter performance was weaker year on year, affected by a high base in the US and weak active pharmaceutical ingredient sales.
Revenue and net profit grew sequentially, supported by India business growth, branded prescription therapies and improving US traction.
Cipla retained its FY27 Ebitda margin guidance of 18.5%-20%.
- Who
- Cipla, the Indian pharmaceutical company.
- What
- It expects its US business to recover, supported by respiratory launches and biosimilars. It also plans 45-50 filings over the next three years.
- When
- The report was published on 2026-10-28. Cipla expects growth momentum in the second half of FY27.
- Where
- The US is the focus of the expected recovery; Cipla also operates in India and has a biosimilar agreement covering the US and Canada.
- Why
- Respiratory launches, a better product mix and improving US traction are expected to support growth.
This story does not have two clearly opposing sides.
Cipla recorded US revenue of $780 million.
The company’s year-on-year performance was affected by a high base in its US business and weak API sales.
Cipla plans to strengthen its organic pipeline through 45-50 filings.
Cipla expects US revenue to exceed $1 billion.
- Expected US revenue by end of FY27
- Over $1 billion
- US revenue in previous year
- $780 million
- Planned filings over next three years
- 45-50
- FY27 Ebitda margin guidance
- 18.5%-20%
- Net cash position
- ₹9,823 crore